Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) EBITDA (2016 - 2025)

Fortress Biotech has reported EBITDA over the past 13 years, most recently at $58.4 million for Q4 2025.

  • Quarterly results put EBITDA at $58.4 million for Q4 2025, up 345.07% from a year ago — trailing twelve months through Dec 2025 was -$7.2 million (up 93.48% YoY), and the annual figure for FY2025 was -$7.0 million, up 93.64%.
  • EBITDA for Q4 2025 was $58.4 million at Fortress Biotech, up from -$6.8 million in the prior quarter.
  • Over the last five years, EBITDA for FBIO hit a ceiling of $58.4 million in Q4 2025 and a floor of -$62.0 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$36.5 million (2024), compared with a mean of -$32.4 million.
  • Biggest five-year swings in EBITDA: plummeted 155.12% in 2021 and later surged 345.07% in 2025.
  • Fortress Biotech's EBITDA stood at -$62.0 million in 2021, then rose by 11.88% to -$54.6 million in 2022, then soared by 64.1% to -$19.6 million in 2023, then dropped by 21.52% to -$23.8 million in 2024, then surged by 345.07% to $58.4 million in 2025.
  • The last three reported values for EBITDA were $58.4 million (Q4 2025), -$6.8 million (Q3 2025), and -$36.5 million (Q2 2025) per Business Quant data.